Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why

Entrada Therapeutics, Inc. (NASDAQ:TRDA) stock is trading lower on Thursday as the stock reacts to news regarding its clinical trial data in Duchenne muscular dystrophy patients.